Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus penpulimab as neoadjuvant therapy for HER2-expressing cisplatin-intolerant muscle-invasive bladder cancer
ChiCTR2200063369Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of disitamab vedotin and penpulimab in transitional cell carcinoma of the bladder (TCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: pathological complete response rate. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
disitamab vedotinpenpulimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2200063369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063369.